# ITIL-168

Source: https://onco.cc/drugs/itil-168/  
OnCo record `itil-168` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ITIL-168 is an autologous tumour-infiltrating lymphocyte cell therapy from Instil Bio that reached phase 2 for advanced cutaneous melanoma, cervical cancer and head and neck squamous cell carcinoma and other cancers; development has stopped.

## Summary

ITIL-168 is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy from Instil Bio. A cell therapy made from the patient's own tumour-infiltrating lymphocytes, grown from a piece of resected tumour. Its furthest stage is phase 2, for advanced cutaneous melanoma, cervical cancer, head and neck squamous cell carcinoma and non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Instil's Form 10-K for 2025 (filed March 2026) says it discontinued its TIL programme and the ITIL-168 and ITIL-306 trials 'several years ago'. NCT05050006 (phase 2, melanoma) TERMINATED; NCT05393635 (phase 1, solid tumours) WITHDRAWN. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest; discontinued
- Code: ITIL-168
- Modality: Autologous tumour-infiltrating lymphocyte (TIL) cell therapy
- Mechanism: A cell therapy made from the patient's own tumour-infiltrating lymphocytes, grown from a piece of resected tumour.

## Sources

- Instil Bio: sec.gov: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm
- Instil Bio: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05050006
- ClinicalTrials.gov: trials of ITIL-168: https://clinicaltrials.gov/search?intr=ITIL-168

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Instil Bio](https://onco.cc/companies/instil-bio/)
- trials: [ITIL-168 in Advanced Melanoma](https://onco.cc/trials/nct05050006/), [ITIL-168 in Advanced Solid Tumors](https://onco.cc/trials/nct05393635/)

---
JSON: https://onco.cc/api/v1/entities/itil-168.json